Biotechnology company Enveric Biosciences (NASDAQ: ENVB) said it is prioritizing the development of EB-003, a compound designed to treat mental health disorders without hallucinogenic effects. The company said EB-003 is intended…
Read More
This past week, an FDA advisory committee voted 9-2 to reject the validity of therapy-assisted MDMA clinical trials conducted by Lykos Therapeutics for the treatment of PTSD. The FDA does…
A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to…
Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million…
Enveric Biosciences signed a non-binding term sheet to out-license a class of novel psilocin products to MinBio Therapeutics for up to $66.5 million in milestone payments. Full Article >>
Enveric Biosciences reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. “We believe the first quarter of 2024 was a highly productive period…
Psychedelics started 2024 with a bang, and the innovative medicines are continuing to gain traction as the year progresses. This week saw one of the globe’s top five biggest pharmaceutical…
On the heels of its announced partnership with MindBio (CNSX: MBIO) this week, Enveric Biosciences (NASDAQ: ENVB) said that it is trying to nail down potential licensing contracts for more…
MindBio Therapeutics (CNSX: MBIO) and Enveric Biosciences (NASDAQ: ENVB) are collaborating to advance treatments for neuropsychiatric disorders through microdosing psychedelics, such as their novel psilocin prodrug candidates. This partnership represents…
Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics for the out-licensing of a class of psilocin prodrugs (NPP) aimed at treating mental health disorders. The NPP molecules…
